BEARINGPOINT
24.11.2022 13:16:34 CET | Business Wire | Press release
Management and technology consultancy BearingPoint’s latest study suggests mobility decisions will be very different by 2030. The study, “Destination 2030, Who’s in the driving seat for the future of mobility?” identified three trends that will drive mobility in the coming years:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221124005066/en/
Destination 2030 - who’s in the driving seat for the future of mobility? (Graphic: Business Wire)
1.) every journey will become a personalized experience
2.) climate neutrality will be non-negotiable – from the cradle to the grave
3.) users will consume services rather than own vehicles.
“It will be a radically different mobility ecosystem that will affect automotive manufacturers, transportation providers, and even energy suppliers as well as tech and insurance companies. What changes is how services are provided and consumed, and these industries must start preparing now. The growth of personalized mobility, mobility as a service and the push towards carbon-neutrality will all profoundly impact the way we think about travel. We’ll control our travel experiences in a new way, and this will impact our relationship with car brands, potentially weakening their ownership of us as customers,” said Dr. Stefan Penthin, global leader Automotive, Industrial Equipment & Manufacturing at BearingPoint.
Remote work, energy crises, climate change and supply chain disruptions are profoundly changing the demand for mobility
The study drew from BearingPoint’s internal research, the views of clients across all industry sectors and input from the consultancy’s sector and technology leaders. The study says remote work, energy crises, climate change and supply chain disruptions are profoundly changing the demand for mobility and the direction and pace of change.
“87% of the survey participants believe they will commute less frequently to work and 81% said they will take significantly fewer business trips compared to 2019, and if this trend continues, it will impact investment in infrastructure. The increased costs associated with developing new mobility infrastructure cannot be passed on entirely to the end user. Legislation may also need to be implemented to achieve the right infrastructure to support electric vehicles. Licensing and enforcement will shift focus from the individual to the provider,” said Andrew Montgomery, global leader Government and Public Sector at BearingPoint.
Three trends that will drive mobility in the coming years
The study sees every journey becoming a personalized experience. Public transportation will shift toward individual mobility, with schedules dictated by consumer needs, rather than predefined as with traditional public transportation. This will lead to more user-centric offerings, making traveling time more productive.
Climate neutrality will be non-negotiable, according to the study, which points to 80% of manufactured engines being green by 2030. Investment will increase in zero-impact modes and related infrastructure, particularly those that promote well-being, such as walking and cycling. And half of the participants (49%) say that they would sacrifice vehicle ownership to reduce their environmental footprint by 2030.
As users will consume services rather than own vehicles, they will switch to on-demand services rather than owning an underutilized vehicle. The services and software will be more important to the general consumer than the physical vehicle and brand, as software platforms will orchestrate the entire journey. 81% of participants point out that they will prefer to use one single app/platform for ordering and billing all their mobility-related services. The study also sees new entrants as constructors, not disruptors.
For more details, please read the full article here: https://www.bearingpoint.com/en/insights-events/insights/destination-2030/
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 13,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221124005066/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 14:28:00 CEST | Press release
CTIBIOTECH™, a leading innovator in advanced human tissue engineering, proudly announces CTIONCOTEST™ platform is awarded Major Bpifrance Funding to Industrialize 3D Bioprinted Cancer Models CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the pla
BMG and Concord Combine to Create World’s Leading Independent Music Company28.4.2026 14:11:00 CEST | Press release
Creates global platform to deliver superior service to artists, songwriters, and partnersUnlocks meaningful value through greater scale and strong cash flow, enabling continued investment in music rights, creative talent, and technologyBob Valentine to serve as CEO and Thomas Coesfeld as Chairman of the combined company, with global headquarters in Nashville and European Headquarters in BerlinCombined company to be named BMG with divisions “BMG Publishing” and “Concord Records” BMG and Concord today announced a definitive agreement to combine their businesses, creating the leading independent music company in the world. Operating under the BMG name, the combined company will bring together two highly complementary businesses to establish a scaled, global company delivering superior service to artists, songwriters, and partners – firmly grounded in an independent, artist-first model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/ho
Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study28.4.2026 14:00:00 CEST | Press release
NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race and Zero Occult Hypoxemia in Black or Hispanic Newborns Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical bias. Importantly, there were no clinically meaningful skin pigmentation-related discrepancies and no occult hypoxemic events among Black or Hispanic patients, and in only one Caucasian patient overall. The Neonatal Pulse Oximetry Accuracy and Disparities by Skin Pigmentation (NeoPODS) study findings were presented from the podium at the Pediatric Academic Society in Boston, MA on Monday, April 27th at 10 am EST by lead author Dr. Heather Siefkes on behalf of colleagues at the University of California, Davis and the University of Mississippi
KAYTUS AI Compute Pod Wins 2026 iF Design Award and Red Dot Award, Setting a New Standard for AI Data Center28.4.2026 11:54:00 CEST | Press release
Delivering up to 130kW of liquid cooling per rack, the solution synchronizes cooling output with IT load in real time within seconds, to support high-density AI, large-scale computing, and HPC deployments, while reducing build time by 70% KAYTUS, a leading provider in AI infrastructure and liquid-cooling solutions, announced that its AI Compute Pod has received both the 2026 iF Design Award and Red Dot Award. This dual recognition not only stems from its outstanding performance in green, low-energy operation—achieving up to 130 kW cooling capacity per rack and a PUE as low as 1.1 through optimized thermal and power design—but also from its innovative approach to intelligent control and efficient O&M. The solution enables second-level synchronization between cooling and IT workloads, and leverages a dual-group control strategy to improve cooling energy efficiency by over 10%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260
Braskem to Showcase Sustainable Packaging Solutions at interpack 202628.4.2026 10:00:00 CEST | Press release
Braskem delivers scalable circular solutions that strengthen the packaging value chain and advance a lower‑carbon future. Braskem (B3: BRKM3, BRKM5, and BRKM6, NYSE: BAK, LATIBEX: XBRK) the largest polyolefins producer in the Americas, as well as a global market leader and pioneer producer of biopolymers on an industrial scale, will be at interpack 2026 in hall 9, booth A32, presenting packaging solutions made from bio-based, recycled and traditional polyolefins, enabling circular plastics, end-to-end. At interpack, Braskem will highlight I’m green™ bio‑based polyethylene grades specifically engineered for food‑contact applications, as well as Medcol V7040, a new grade for Healthcare and Hygiene. These innovations mark the first time Braskem has offered sustainably sourced sugarcane‑derived plastics for these segments. In an environment where packaging decisions are increasingly evaluated on both sustainability ambitions and business impact, Braskem positions itself as a materials part
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
